Personalized treatment of early-stage breast cancer: present concepts and future directions.
Breast cancer is the most common malignancy in women. Effective loco-regional as well as systemic treatment options have rendered breast cancer a curable disease for the vast majority of early-stage patients. Considering tumor biology and clinical outcomes, breast cancer is a very heterogeneous disease. With the recent understanding of distinct molecular sub-types, the era of "one size fits all" therapy concepts has passed and a new era of personalized therapy concepts has started. This review will focus on recent advances in personalized treatment of early-stage breast cancer, with a particular interest in tumor biology-guided treatment decisions. It will also highlight how carefully molecular tests need to be methodologically and clinically validated before they can be applied for clinical decision making.
Harbeck
Nadia
N
Breast Center, Department of Gynecology and Obstetrics, University Hospital Köln, Cologne, Germany. nadia.harbeck@uk-koeln.de
Salem
Marwa
M
Nitz
Ulrike
U
Gluz
Oleg
O
Liedtke
Cornelia
C
D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood; D001707:Biopsy, Needle; D001943:Breast Neoplasms / Q000097:blood / Q000235:genetics / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D055088:Early Detection of Cancer; D005260:Female; D005544:Forecasting; D006801:Humans; D007150:Immunohistochemistry; D008327:Mammography / Q000379:methods; D008875:Middle Aged; D009367:Neoplasm Staging; D057285:Precision Medicine / Q000379:methods*; D011379:Prognosis; D018714:Radiotherapy, Adjuvant; D016019:Survival Analysis; D016896:Treatment Outcome
D014408:Biomarkers, Tumor